Naushad Naufal, Deb Abdalla A, Agag Ayman A, Serag Hosam A, Sangar Vijay K
Department of Urology, Christie NHS Foundation Trust, Manchester, UK.
Department of Urology, James Cook University Hospital, Middlesbrough, UK.
Urol Res Pract. 2023 May;49(3):138-146. doi: 10.5152/tud.2023.22225.
New tumor biomarkers open the potential for designing personalized therapy for penile squamous cell carcinoma. Despite the initial promising results of some biomarkers, controversy remains due to contradictory studies. Further robust research work is required before incorporating biomarkers in the personalized management of penile cancer. This narrative review aims to highlight some of the most commonly and recently investigated biomarkers of penile cancer and to summarize the ongoing registered clinical trials for the management of penile cancer patients.
新的肿瘤生物标志物为阴茎鳞状细胞癌的个性化治疗设计带来了可能性。尽管一些生物标志物最初取得了令人鼓舞的结果,但由于研究结果相互矛盾,争议仍然存在。在将生物标志物纳入阴茎癌的个性化管理之前,还需要进一步强有力的研究工作。这篇叙述性综述旨在强调一些最常用和最近研究的阴茎癌生物标志物,并总结目前正在进行的针对阴茎癌患者管理的注册临床试验。